trial · primary record
8-Chloroadenosine
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 20 |
| Primary completion | 2021-03-16 |
| Primary endpoint | Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) |
| Registry ID | NCT02509546 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:46.636Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02509546
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.